Viewing nowCombinationVitame M Tablets 50/500mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.

MFDS item code 202302026 · Approved 2023.06.30 · Insurance code 644309720
Improves blood glucose control in patients with type 2 diabetes mellitus
This medication helps control blood sugar in patients with type 2 diabetes by combining sitagliptin and metformin. When used alongside dietary and exercise therapy, it can effectively improve blood sugar levels. This contributes to diabetes management and aids in the prevention of complications. It is important for patients to take this medication consistently while maintaining healthy lifestyle habits. This medication is used to improve blood sugar control in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. Generally, take this medicine twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Patients in whom this medicine must not be administered). 2. Patients receiving metformin: - For patients with inadequate glycemic control on metformin monotherapy, the recommended initial dose is the current metformin dose together with sitagliptin 50 mg twice daily (total daily dose 100 mg). - Patients switching from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial metformin dose should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that could increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500 mg or 850 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment Because this medicine contains metformin, it should not be administered to patients with hepatic impairment (see Precautions, 2. Patients in whom this medicine must not be administered).
This medication contains sitagliptin and metformin, which are used in diabetes treatment. First, the sitagliptin component can rarely cause serious allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a doctor. Additionally, there have been reports of a serious side effect called acute pancreatitis, which is inflammation of the pancreas; if symptoms such as abdominal pain, vomiting, or fever occur, inform healthcare professionals immediately. The metformin component may cause a rare side effect known as lactic acidosis, which is a condition where lactic acid builds up excessively in the body, leading to severe fatigue, muscle pain, difficulty breathing, or abdominal pain. Patients with poor kidney function, liver disease, severe infections, or dehydration should not take this medication. Before and after undergoing tests with iodinated contrast agents, this medication should be temporarily discontinued as it may affect kidney function, and it should be resumed only after kidney function is confirmed to be normal. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication. During treatment, be cautious of symptoms of hypoglycemia, especially when used alongside other antidiabetic agents or insulin, as the risk of hypoglycemia may increase. It is crucial for patients to maintain regular meals and exercise and to have their blood sugar and kidney function regularly checked. Moreover, when taking this medication, the risks may increase when consumed with alcohol, so it is advisable to avoid alcohol. If any unusual symptoms such as severe joint pain or skin blisters arise during use, inform a doctor immediately and discontinue the medication. In case of overdose, seek medical attention immediately for appropriate treatment, as some components can be removed through hemodialysis. Finally, regular blood tests and kidney function tests are necessary to ensure safe treatment while taking this medication.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. It is advisable to keep it at room temperature between 1 to 30 degrees Celsius. This way, the effectiveness of the medication can be safely maintained.
Pink oval film-coated tablet
60 tablets (10 tablets/PTP x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.